| Project/Area Number |
16K18959
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Musashino University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
ITO Kiyomi 武蔵野大学, 薬学研究所, 教授 (60232435)
HIROYA Kou 武蔵野大学, 薬学研究所, 教授 (70192721)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | metronidazole / 薬物相互作用 / 薬物代謝酵素 / トランスポーター / 薬学 / 酵素 |
|---|
| Outline of Final Research Achievements |
In order to elucidate the mechanism of drug-drug interactions caused by metronidazole (MTZ), a widely used anti-fungal agent, and to investigate the possibility of unknown interactions, in vitro studies were performed using human liver-derived sources. As a result, MTZ was found not to have pronounced effects on the metabolic activities and expression of major drug-metabolizing enzymes and on the expression of hepatic uptake transporters at the clinically relevant concentrations, suggesting that MTZ is not likely to cause drug-drug interactions via those enzymes/transporters in clinical practice. In the future, investigation of the effects of MTZ metabolites would contribute to the clarification of the mechanism of reported interactions caused by MTZ and appropriate use of MTZ in clinical practice.
|
